EligibleTrials

Clinical trials recruiting for KRAS G12C

3
Recruiting trials
16
US states with sites
3
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 2Phase 2 2

Drugs and treatments being studied

InterventionTrials
Adagrasib1
BBO-102031
BBO-118181
Cetuximab1
FMC-3761
Gemcitabine1
Nab-paclitaxel1
Pembrolizumab1
Pemetrexed1
Platinum chemotherapy (cisplatin or carboplatin)1
Stereotactic Radiosurgery1
mFOLFIRINOX1

Where trials are recruiting (top US states)

StateRecruiting trials
California2
Florida2
Massachusetts2
Texas2
Utah2
Virginia2
Connecticut1
Illinois1
Indiana1
Kansas1
Michigan1
New York1

Top cities

Boston, Massachusetts 2Houston, Texas 2San Antonio, Texas 2San Francisco, California 2Charlottesville, Virginia 1Columbus, Ohio 1Dallas, Texas 1Detroit, Michigan 1Dyer, Indiana 1Fairfax, Virginia 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for KRAS G12C often also study these conditions. Each links to its own recruiting-trial list.

Non-small cell lung cancer 507Lung cancer 2180Solid Tumor, Adult 38Pancreatic cancer 870Colorectal cancer 1359Unresectable Solid Tumor 5PDAC - Pancreatic Ductal Adenocarcinoma 21Metastatic Solid Tumor 22Metastatic Pancreatic Ductal Adenocarcinoma 12Metastatic Colorectal Cancer (CRC) 17

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for KRAS G12C trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.